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R102G gene polymorphisma b s t r a c t
Background: Genetic and environmental factors are known to be risk factors in development of neovas-
cular age-related macular degeneration (nAMD). Genetic factors such as polymorphisms in the comple-
ment component pathway genes might play a role in pathogenesis of nAMD and has been studied in
various populations excluding Malaysia.
Aim of the study: To determine the association of the R102G polymorphism of the complement component
(C3) gene in nAMD subjects.
Patients and methods: A total of 301 Malaysian subjects (149 case and 152 controls) were recruited and
genotyped for the R102G (rs2230199) variant of the C3 gene. Genotyping was conducted using the PCR-
RFLP method and association analysis was conducted using appropriate statistical tests.
Results: From our findings, no significant association was observed in the allele distribution of C3 R102G
between nAMD and controls (OR = 1.42, 95% CI = 0.77–2.62, P = 0.268). A further analysis that compared
three genetic models (dominant, recessive and co-dominant) also recorded no significant difference
(P > 0.05). These findings could be due to the low frequency of the GG variant in the case (4.7%) and con-
trol (1.3%) groups, compared to the normal variant CC, which is present in 91.3% of case and 92.8% of con-
trol alleles.
Conclusion: The present study showed no evidence of association between C3 R102G polymorphism and
nAMD in Malaysian subjects.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Age-relatedmacular degeneration (AMD) is a complex multifac-
torial and heterogeneous disease that results in progressive degen-
eration of the macula [1]. The most advanced form of AMD, is
neovascular (wet or exudative) (nAMD), which can lead to a sud-
den deterioration of vision due to a hemorrhage or fluid leakingfrom abnormal blood vessels developing underneath the macula
[2]. Although the etiology of AMD remains elusive, due to the pres-
ence of inflammatory proteins and immune-mediated processes in
drusen, a pathological deposit that forms between the Bruch’s
membrane and retinal pigment epithelium (RPE), inflammation
has been suggested as the pathogenesis of AMD [3].
Increasing numbers of molecular studies have emerged provid-
ing better insights into the molecular pathology of AMD, such as
single nucleotide polymorphisms (SNPs) of candidate genes related
to inflammatory processes in the complement system involving
the biogenesis of drusen [4]. The complement system is a complex
of many enzymes and regulators; however, complement compo-
nent activation, in particular C3a, the cleavage product of comple-
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has been proposed to be a risk factor in AMD [5]. The progression
of choroidal neovascularization (CNV), cell degeneration and the
formation of drusens in AMD has been suggested due to dysfunc-
tional in the complement system [6], and the plasma complement
concentrations of arginine (Arg) that is terminally cleaved from the
C3a parent molecule has also been reported to be higher among
AMD subjects compared to normal subjects [7], reflecting C3 gene
as a possible risk factor to AMD.
The human C3 gene is located on chromosome 19 and the
R102G (rs2230199 C > G), a non-synonymous SNPs of the C3 gene
which causes an amino acid change from arginine to glycine, has
been studied in various populations but presents contradictory
findings [8,9]. These inconsistent results encourage further investi-
gation into the correlation between C3 and AMD among the Malay-
sian population, especially among the nAMD subtype. Moreover, it
has been reported that genetic heterogeneity of complex diseases
is common in different ethnic groups [10]; thus, the variants of
an Asian population might not be similar to a population of Euro-
pean descent. Furthermore, to our knowledge, there are not yet any
studies on C3 gene polymorphisms and nAMD in Malaysians,
which led us to conduct this study on the effects of C3 R102G gene
polymorphisms and their association with nAMD subjects in
Malaysia.2. Patients and methods
2.1. Patients selection
This study includes 149 nAMD patients and 152 controls
recruited from the Ophthalmology Clinic in two tertiary centers,
Hospital Selayang and Universiti Kebangsaan Malaysia Medical
Center (UKMMC). Sample size was calculated by aiming at 80% sta-
tistical power. Prior to recruiting the subjects, ethical approval was
obtained from the institutional review board of Universiti Putra
Malaysia (UPM), Universiti Kebangsaan Malaysia (UKM) and Med-
ical Research Committee (MREC) of the National Medical Research
Registry (Ethics No: NMRR-14-1176-21475); and the work has
been carried out in accordance with The Code of Ethics of The
World Medical Association (Declaration of Helsinki) for experi-
ments in humans. Consent was obtained from all subjects before
recruiting them in the study and socio-demographic and medical
history of each subject was recorded.
Subjects received a comprehensive ophthalmic examination by
ophthalmologists in the respective centers and diagnosis of nAMD
was confirmed based on fundus examination, optical coherence
tomography (OCT), fluorescein angiography (FA) and clinical
examinations.
2.2. Inclusion and exclusion criteria
Subjects aged > 50 years, diagnosed with nAMD after undergo-
ing comprehensive ophthalmic examinations and presence of
choroidal neovascularization (CNV) in either or both eyes, were
included in this study. CNV resulting from the other causes and
the other retinal diseases were excluded. Subjects aged > 50 years
with no clinical evidence of nAMD or retinal disorders were
recruited as control samples.
2.3. Gene and SNP selection
Twenty five associated candidate genes for AMDwere identified
from recent AMD genome wide association studies and previous
association studies [11,12]. Using the search terms: age-related
macular degeneration, AMD, SNP, association study or polymor-phism; literature reviews were obtained from the online journal
databases. R102G of the C3 gene was one among the significantly
associated gene with AMD in many populations (Table 1) but not
studied among Malaysians and thus, C3 gene polymorphisms was
selected as a candidate SNP in the present study. Also, the SNP
was selected based on the functional significance, location and
minor allele frequency of >10% [13,14].
2.4. Genotyping
Polymerase chain reaction – restriction fragment length poly-
morphism (PCR-RFLP) method was used to genotype the
rs2230199 (R102G) SNP of C3 gene. Peripheral venous blood was
collected from all subjects into 5 mL EDTA tubes. Genomic DNA
was extracted from collected blood samples using QIAamp DNA
blood mini kit (Qiagen, Valencia, CA, USA). The PCR was then car-
ried out in a thermo cycler (Thermo Fisher Scientific, Waltham,
MA USA) in a total volume of 25 ml with the following primers: for-
ward: 50-CTCACCTGTGGAGCCAGGGGTGT A-30 and reverse: 50-CC
AAAACGGCCACCTCGGAAGACC-3. Genomic DNA amplification
was performed by performing 35 cycles of denaturing at 95 C
for 60 s, annealing at 55 C for 60 s and extending at 72 C for
30 s, followed by a single final extension at 72 C for 5 min. The
HhaI restriction enzyme (New England Biolabs, Beverly, MA, USA)
was then used to digest the amplified product at 37 C for 3 h.
PCR and digested products were separated on a 3% agarose gel then
visualized using a UV alpha imager (Alpha Innotech, San Leandro,
CA).
2.5. Statistical analysis
Student’s t-test and chi-square test were used to analyse the
variables. Frequencies of alleles were estimated using the allele
counting method and Hardy-Weinberg equilibrium assessed. The
association of rs2230199 to nAMD was evaluated by logistic
regression test using genotype and allele frequencies. A logistic
regression model that assumed a co-dominant, dominant and
recessive model was used to calculate the odds ratio (ORs) and
95% confidence intervals (CIs) of nAMD; the case and control
groups were compared. All statistical analyses were performed
using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) and P < 0.05
was considered to be statistically significant.3. Results
The case group reported a significantly higher mean age
(68.6 ± 8.47 years) compared to the control group
(64.8 ± 10.21 years, P < 0.001). The ethnicity of the subjects also
differed significantly (P = 0.009) with most nAMD cases being eth-
nically Chinese (57%) whereas Malay presented the highest ethnic-
ity in the control group (42%). Among the co-morbidities recorded,
diabetes was significant among controls (13%, P = 0.036) while
hypertension was significant among nAMD cases (36%, P = 0.001).
There is also a significant difference frequency of smoking, with
cases reporting 37% and controls 19% (P < 0.001). Gender and dia-
betes with hypertension did not show any significant difference
between cases and controls (P > 0.05). Table 2 represents the
demographic features of the study population.
Genotyping using the PCR-RFLP method was performed as
shown in Fig. 1. The high- risk GG genotype of rs2230199 was
recorded to be low in both cases and controls, with frequency of
7 (4.7%) and 2 (1.3%), respectively. The allele distribution of the
G allele was also very low in cases and controls, at 6.7% and 4.3%,
respectively. Further analysis showed that when compared to
low-risk CC genotype and C allele, neither the GG genotype or G
Table 1
Association of C3 R102G gene polymorphism in other studies.
Author Location Ethnicity Sample (cases/controls) Casesa Controlsa Associationb
W M W M
Yates et al. [16] England, Scotland Caucasian 603/350 848 (0.72) 332 (0.28) 555 (0.80) 137 (0.20) Yes
Spencer et al. [22] USA Caucasian 701/286 NA 203 (0.29) NA 60 (0.21) Yes
Scholl et al. [23] USA Caucasian 99/612 143 (0.73) 51 (0.26) 964 (0.83) 204 (0.17) Yes
Cui et al. [18] China Asian 150/161 297 (0.99) 3 (0.01) 321 (0.99) 1 (0.03) No
McKay et al. [24] Northern Ireland Caucasian 437/436 615 (0.70) 259 (0.30) 679 (0.78) 193 (0.22) Yes
Zerbib et al. [25] France Caucasian 1080/406 1600 (0.74) 560 (0.26) 639 (0.79) 173 (0.21) Yes
Chen et al. [26] San Diego Caucasian 1335/509 NA 0.28 NA 0.19 Yes
Kim et al. [21] Korea Asian 153/197 306 (1.00) 0 (0) 394 (1.00) 0 (0) No
Tian et al. [17] China Asian 535/469 1060 (0.99) 4 (0.01) 928 (0.99) 2 (0.01) No
Wu et al. [19] China Asian 165/216 328 (0.99) 2 (0.01) 428 (0.99) 4 (0.01) No
Contreras et al. [27] Mexico Caucasian 273/201 NA NA NA NA Yes
Havvas et al. [28] Greek Caucasian 120/140 NA 40 (0.34) NA 30 (0.22) Yes
Present study Malaysia Asian 149/152 278 (0.93) 20 (0.07) 291 (0.96) 13 (0.04) No
W = normal allele; M = mutant allele; NA = data not available.
a Data are reported as number of subjects with percent in parentheses.
b Association among AMD patients vs. controls.
Table 2
Demographics of study population.
Cases (n = 149) Controls (n = 152) Pa
Age (years) 68.6 ± 8.47 64.8 ± 10.21 <0.001b,*
Gender Male 95 (64.0) 112 (74.0)
Female 54 (36.0) 40 (26.0) 0.063
Race Malay 51 (34.0) 64 (42.0)
Chinese 85 (57.0) 62 (41.0)
Indian 13 (9.0) 26 (17.0) 0.009*
Co-morbidities DM 9 (6.0) 20 (13.0) 0.036*
HPT 53 (36.0) 29 (19.0) 0.001*
DM + HPT 40 (27.0) 38 (25.0) 0.715
Smoking 56 (37.0) 28 (19.0) <0.001*
Data presented as mean ± SD for mean age and data are reported as number of subjects with percent in parentheses.
DM = diabetes mellitus; HPT = hypertension.
a Chi-square test, P < 0.05.
b Student t-test, P < 0.01.
* Significant P-value, P < 0.05.
Fig. 1. PCR-RFLP product for C3 R102G gene polymorphism on 3% agarose gel. Lane
1 shows RFLP product for homozygous GG at 300-bp. Lane 2 until lane 8 shows RFLP
product for homozygous CC at 133-bp and 167-bp. Lane 9 shows RFLP product for
heterozygous CG at 133-bp, 167-bp and 300-bp.
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(P = 0.073, P = 0.268, respectively) (Table 3).
Including age, ethnicity, diabetes, hypertension and smoking as
covariates in the logistic regression model did not substantially
change the significance of the association (Table 4). None of the
three genetic models showed significant differences between sub-
jects with P = 0.718 in a dominant model, P = 0.064 in a recessive
model and P = 0.068 in a co-dominant model. However, in a reces-
sive genetic model, the OR 4.67 (95% CI = 0.91–23.87) for subjects
carrying the GG mutant genotype was higher when compared to
CG + CC genotypes; this was followed by a co-dominant model
OR 2.14 (95% CI = 0.95–4.84) for subjects carrying the GG mutant
genotype compared to those with the normal CC genotype. Thedominant model that compares between normal CC genotype with
CG + GG genotypes had the least OR with 1.18 (95% CI = 0.48–2.91).4. Discussion
This study evaluated the association of R102G SNPs
(rs2230199) of C3 with nAMD in a Malaysian population and
observed no significant association to nAMD even after adjusting
for confounding factors, as the risk-associated G allele was
recorded to be very low in cases and controls. Based on findings
that suggest R102G is strongly correlated with AMD, the R102G
polymorphism was included in the present study and compared
to other polymorphisms in the C3 gene. Amino acid changes from
R102G may alter configuration of the macroglobulin ring causing
alteration in the binding to other complement proteins or patho-
genic cell surface [8].
The R102G also produces two electrophoretic allotypes of C3,
the C3F (fast variant) and C3S (slow variant) [15]; it is the C3F allo-
type that has been associated with AMD [16]. Association between
R102G SNPs in C3 has also been extensively studied in other pop-
ulations, but with contradictory findings, as summarized in
Table 1.
The present finding is consistent with other relevant Asian stud-
ies such as Tian et al., Chinese population study that also recorded
a low number of risk G allele and found no significant association
to AMD [17]. Findings from a meta-analysis of R102G and AMD
that included 15 independent case-control studies also concluded
Table 3
Genotypes and allele frequencies and odds ratios in cases and controls.
Genotype Cases Controls OR (95% CI)a Pa
CC 136 (91.3) 141 (92.8) 1.00 (Reference)
CG 6 (4.0) 9 (5.9) 0.55 (0.17–1.71) 0.299
GG 7 (4.7) 2 (1.3) 4.46 (0.87–22.87) 0.073
C allele 278 (93.3) 291 (95.7) 1.00 (Reference)
G allele 20 (6.7) 13 (4.3) 1.42 (0.77–2.62) 0.268
CI = confidence interval; OR = odds ratio.
a Logistic regression analysis.
Table 4
Genotype association of nAMD based on dominant, recessive and co-dominant
models.
Genetic model OR (95% CI) for nAMD)a P-valuea
Dominant (CC vs. CG + GG) 1.18 (0.48–2.91) 0.718
Recessive (GG vs. CG + CC) 4.67 (0.91–23.87) 0.064
Co-dominant (GG vs. CC) 2.14 (0.95–4.84) 0.068
CI = confidence interval; OR = odds ratio.
a Logistic regression analysis, adjusted for age, ethnicity, diabetes, hypertension
and smoking.
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Caucasians but not among Asians, as the risk G allele was recorded
low in most Asian populations [6]. Other studies that reported no
significant association of rs2230199 and AMD are from China
[18–20] and Korea [21].
Although the risk variant of R102G is rare among Asians, the
frequency is almost 20% among the European descents [9], thus
suggesting that the variant may be associated with development
of AMD. This is further supported by findings frommultiple studies
[16,22–28] that report an association of R102G with AMD suscep-
tibility, which are all among the Caucasian populations. In a most
recent meta-analysis study of C3 risk to AMD involving 10,531
AMD individuals and 12,051 controls, the G allele of R102G was
identified as a risk factor among Caucasians, but not in Asians
[8], further supporting findings in this study.
Some limitations in the present study should be taken into con-
sideration. Firstly, the relatively small number of samples could
contribute to the lack of association and also the low frequency
of the risk allele being studied. Secondly, the heterogeneity of
patients, consisting of three multi-ethnics in Malaysia, could also
affect the findings as different ethnicities might have different
genetic profiles. Thirdly, there was no analysis of the C3 expression
levels, which could be a risk factor for R102G. Moreover, there is
the potential of nAMD being modified by the other genetic factors
in the complement pathway apart from the C3 gene such as the
complement factor H (CFH) and complement factor 1 (CF1) genes
and other variants may play a role in pathogenesis of AMD in the
Malaysian population.
In conclusion, there was no significant association between C3
R102G gene polymorphism and the risk of nAMD among Malay-
sians. A larger sample size with variable SNPs should be conducted
in future studies to identify further risk-associated variants related
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